RHHBYPDUFA
Gazyva®/Gazyvaro® (obinutuzumab) (CD20 Antibody)
Primary Membranous Nephropathy
Approval decisionFDA regulatory calendar
Track FDA action dates and advisory committee meetings by month. Each event links to its company, drug, indication and source-backed research record.
FDA regulatory calendar
Primary Membranous Nephropathy
Approval decisionEarly-Stage ER-Positive HER2-Negative Breast Cancer
Approval decisionUse the monthly FDA calendar to review PDUFA target dates and advisory committee meetings, then open each event for drug, company, indication and source context.
Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
Approval decision